WO2000050057A1 - Compositions and methods for prevention of photoaging - Google Patents
Compositions and methods for prevention of photoaging Download PDFInfo
- Publication number
- WO2000050057A1 WO2000050057A1 PCT/US2000/004427 US0004427W WO0050057A1 WO 2000050057 A1 WO2000050057 A1 WO 2000050057A1 US 0004427 W US0004427 W US 0004427W WO 0050057 A1 WO0050057 A1 WO 0050057A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- serine protease
- sun
- alpha
- antitrypsin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- Immunohistochemical staining has shown the poorly-formed fibers comprising solar elastosis to be composed of elastin (Chen et al . , J. Invest . Dermatol . , 1986, 87:334-337; Mera et al . , Br. J. Dermatol . , 1987, 117:21- 27) fibrillin (Chen et al . , J. Invest . Dermatol . , 1986, 87:334- 337; Dahlback et al . , J. Invest . Dermatol . , 1990, 94:284-291; Bernstein et al . , J. Invest . Dermatol .
- Elevated elastin mRNA levels in sun-damaged skin result from enhanced elastin promoter activity, as shown by transient transfections of fibroblasts with a DNA construct composed of the human elastin promoter linked to the chloramphenicol acetyltransferase (CAT) reporter gene (Bernstein et al . , J. Invest . Dermatol . , 1994, 103:182-186).
- CAT chloramphenicol acetyltransferase
- Neutrophil elastase has been suggested to be an important mediator in the development of solar elastosis resulting from continued exposure to UVB (See Abstract from Ciba-Found. Symp., 1995, 192:338-46; discussion 346-7).
- Alpha 1-proteinase inhibitor also referred to herein as alpha 1-antitrypsin
- alpha 1-antitrypsin is approved by the Food and Drug Administration as a plasma product for the treatment of hereditary alpha 1-antitrypsin deficiency.
- Alpha 1-antitrypsin has also been disclosed for use in the treatment of atopic dermatitis (Wachter, A.M. and Lezdey, J. Annals of Allergy, 1992, 69:407-414) .
- Alpha 1-antitrypsin is a member of the serine protease inhibitor (serpin) supergene family. Serpins are a superfamily of inhibitors involved in the mediation of a variety of biological processes essential to survival of a host.
- the serpin with the highest naturally occurring plasma concentration is alpha 1-antitrypsin.
- This serpin has activity toward both tryptic and chymotryptic proteases. It has now been found that topical application of serine proteases such as alpha 1-antitrypsin prevents photoaging and other skin damage resulting from exposure to solar, and more specifically, ultraviolet radiation.
- serine proteases such as alpha 1-antitrypsin. It has now been demonstrated that topical application of alpha- 1 antitrypsin protects against photoaging and other sun-damage such as sunburn and skin cancer caused by solar radiation. Accordingly, serine proteases with alpha 1-antitrypsin-like activities are believed to be useful as sunscreen agents. Compositions for use as sunscreen agents comprising serine proteases with alpha 1-antitrypsin like activities are also provided.
- a transgenic mouse model which contains the human elastin promoter linked to a chloramphenicol acetyltransferase (CAT) reporter gene for testing compounds that may inhibit cutaneous photodamage has been developed. These mice express human elastin promoter activity in a tissue-specific and developmentally regulated manner. Promoter activity can be studied in this model as a function of small increases in ultraviolet radiation, demonstrating the sensitivity of the assay. In addition, quantitative data can be obtained after only a single exposure to ultraviolet radiation.
- a test compound is applied to the skin of a transgenic mouse capable of expressing the human elastin promoter. The transgenic mouse is then exposed to solar radiation and human elastin promoter activity in the mouse is determined.
- mice The human elastin promoter activity is then compared to that in transgenic mice also exposed to an equivalent dose of solar radiation which were not treated with the test compound to determine whether or not the test compound provided protection against the solar radiation. Since elastin promoter activation is a primary event in cutaneous aging, these mice represent a mouse model of human photoaging.
- Alpha 1-antitrypsin is produced in the milk of transgenic goats. Accordingly, in these experiments, 5 mice received either no treatment, 10 mice were treated with a 20 mg/ml solution of alpha 1-antitrypsin in goat's milk applied topically to the back, and 10 mice were treated with a solution of goat's milk alone applied topically to the back. A group of mice was also treated with saline only.
- mice Approximately fifteen minutes after application of the goat's milk containing alpha 1-antitrypsin, goat's milk alone, or saline these mice were exposed to 20 human minimal erythema doses (MEDs) of solar simulating radiation (SSR) . Following phototreatment , the backs of the mice were rinsed twice with 70% isopropyl alcohol pads to remove any excess alpha 1-antitrypsin. This procedure was repeated over three consecutive days.
- MEDs human minimal erythema doses
- SSR solar simulating radiation
- mice were sacrificed and skin harvested for determination of CAT activity 24 hours after the third phototreatment.
- the baseline CAT activity of control mice receiving neither radiation nor alpha 1-antitrypsin was standardized to a value of one.
- Relative increases in CAT activity were 14.4 + 3.1 (mean + S.D.) in mice treated with goat's milk alone and 4.5 + 1.0 in mice treated with goat's milk containing alpha 1- antitrypsin.
- topical application of the serpin alpha 1- antitrypsin produced a 69% reduction in- CAT activity.
- milk alone provided 12% protection as compared to the saline control animals.
- other serpins with alpha 1-antitrypsin-like activities it is meant serine protease inhibitors with similar activity toward both tryptic and chymotryptic proteases as alpha 1-antitrypsin.
- serpins include both naturally occurring serine protease inhibitors and mutants rationally engineered to have similar activities and specificity to alpha 1-antitrypsin. Methods of rationally engineering serine proteases and their inhibitors are known. See, for example, Dang et al . Nature Biotechnology, 1997, 15:146-149.
- compositions comprising a serpin with alpha 1-antitrypsin like activities include, but are not limited to creams, lotions and sprays. Methods of formulating serpins into creams, lotions and sprays as well as pharmaceutical additives for such formulations are well known to those skilled in the art. As will be obvious to those skilled in the art upon this disclosure, such compositions may further comprise secondary or additional sunscreens or free radical scavengers such as, but not limited to, Vitamin C and Vitamin E and analogs thereof.
- a composition comprising a serpin is applied to the skin prior to exposure to the sun. However, application of these compositions subsequent to the exposure can also mitigate any damage resulting to the skin from this exposure.
- compositions of the present invention will be especially useful in protecting individuals with heightened sensitivities to the sun, such as, but not limited to, individuals undergoing psoralen treatment for cancer, psoriasis and other skin conditions; individuals undergoing photodynamic therapy for skin cancer, psoriasis and other skin conditions; individuals suffering from genetic repair defects such as xeroderma pigmentosa, albinism or other conditions resulting from decreased endogenous melanin pigment .
- topical application of a composition comprising milk or a product derived therefrom also provides protection against photoaging and other sun- damage such as sunburn and skin cancer. Accordingly, compositions such as creams, lotions and sprays which comprise milk or a product derived therefrom can also be formulated for use in protecting against photodamage and other sun-damage in normal individuals and those with a heightened sensitivity to the sun .
- Example 1 Transgenic mice expressing the human elastin promoter
- mice expressing the 5.2- kb human .elastin promoter linked to a CAT reporter gene were used. Hsu-Wong et al . , J. Biol . Chem . , 1994, 269:18072-18075. These mice express the human elastin promoter in a tissue- specific and developmentally regulated manner. Mice four or five days old were used since at this age, visible hair growth is not yet present.
- a Multiport Solar Simulator (Solar Light Company, Philadelphia, PA) containing a xenon arc lamp filtered through a Schott WG 320 filter (Schott Glastechnike, Mainz, Germany) was used to administer solar simulating radiation (SSR) .
- SSR solar simulating radiation
- the output of the solar simulator was measured by means of a 3D UV meter (Solar Light Company) and displayed as human minimal erythema doses (MEDs) .
- MEDs minimal erythema doses
- the emission spectrum of the lamp closely simulates solar radiation reaching- the earth's surface.
- the light guides from the solar simulator were placed in light contact with the dorsal surface of the mice, which were restrained to prevent movement while SSR was administered. Unirradiated control mice were also restrained without receiving SSR.
- CAT activity was determined.
- the specimens were homogenized in 0.25 Tris-HCl, pH 7.5, using a tissue homogenizer (Brinkmann Instruments, Inc. Westbury, NY) .
- the homogenates were centrifuged at 10,000 X g for 15 minutes at 4°C and the protein concentration in the supernatant determined by a commercial protein assay kit (Bio- Rad Laboratories, Richmond, CA) .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Zoology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002362565A CA2362565A1 (en) | 1999-02-22 | 2000-02-22 | Compositions and methods for prevention of photoaging |
EP00910265A EP1162934A4 (en) | 1999-02-22 | 2000-02-22 | Compositions and methods for prevention of photoaging |
AU32387/00A AU759261B2 (en) | 1999-02-22 | 2000-02-22 | Compositions and methods for prevention of photoaging |
JP2000600667A JP2002537346A (en) | 1999-02-22 | 2000-02-22 | Photoaging composition and method of protection |
US11/060,041 US20050208000A1 (en) | 1999-02-22 | 2005-02-17 | Compositions and methods for prevention of photoaging |
US13/531,439 US20120263663A1 (en) | 1999-02-22 | 2012-06-22 | Compositions and methods for prevention of photoaging |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12111899P | 1999-02-22 | 1999-02-22 | |
US60/121,118 | 1999-02-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/060,041 Continuation US20050208000A1 (en) | 1999-02-22 | 2005-02-17 | Compositions and methods for prevention of photoaging |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000050057A1 true WO2000050057A1 (en) | 2000-08-31 |
Family
ID=22394673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/004427 WO2000050057A1 (en) | 1999-02-22 | 2000-02-22 | Compositions and methods for prevention of photoaging |
Country Status (6)
Country | Link |
---|---|
US (2) | US20050208000A1 (en) |
EP (1) | EP1162934A4 (en) |
JP (1) | JP2002537346A (en) |
AU (1) | AU759261B2 (en) |
CA (1) | CA2362565A1 (en) |
WO (1) | WO2000050057A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018137400A1 (en) * | 2017-01-26 | 2018-08-02 | 上海交通大学 | Application of cystatins in preparation of drug for treating or preventing ultraviolet light-induced skin damage |
EP3681494A4 (en) * | 2017-09-15 | 2021-08-04 | Ampersand Biopharmaceuticals, Inc. | Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120171144A1 (en) * | 2006-03-09 | 2012-07-05 | David James Granville | Methods of treating, reducing and inhibiting the appearance of ageing in the skin |
US8426149B2 (en) | 2007-10-01 | 2013-04-23 | The University Of British Columbia | Granzyme A and granzyme B diagnostics |
AU2008307047B2 (en) * | 2007-10-01 | 2013-12-19 | The University Of British Columbia | Treatment of dissection, aneurysm, and atherosclerosis using granzyme B inhibitors |
KR20140093603A (en) | 2010-12-30 | 2014-07-28 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | Glycols as pathogen inactivating agents |
AR094778A1 (en) | 2013-02-13 | 2015-08-26 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | PROTEINS WITH MODIFIED GLYCOSILATION AND METHODS FOR PRODUCERS |
KR20160002713A (en) | 2013-02-13 | 2016-01-08 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
WO2014153667A1 (en) * | 2013-03-29 | 2014-10-02 | Vida Therapeutics, Inc. | Cosmetic uses and methods for indoline granzyme b inhibitor compositions |
US9605021B2 (en) | 2013-03-29 | 2017-03-28 | Vida Therapeutics Inc. | Indoline compounds as granzyme B inhibitors |
JP2016532100A (en) | 2013-07-05 | 2016-10-13 | ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーLaboratoire Francais Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
US10537652B2 (en) | 2014-08-01 | 2020-01-21 | Vida Therapeutics Inc. | Cyclic urea compounds as granzyme B inhibitors |
US9458192B1 (en) | 2014-08-01 | 2016-10-04 | Vida Therapeutics Inc. | Covalent granzyme B inhibitors |
EP3186271A4 (en) | 2014-08-01 | 2018-03-14 | Vida Therapeutics, Inc. | Azaindoline compounds as granzyme b inhibitors |
US9458138B1 (en) | 2014-08-01 | 2016-10-04 | viDATherapeutics Inc. | Pyrrole compounds as granzyme B inhibitors |
US9458193B1 (en) | 2014-08-01 | 2016-10-04 | Vida Therapeutics Inc. | Proline compounds as Granzyme B inhibitors |
KR102287153B1 (en) * | 2019-12-27 | 2021-08-06 | 경희대학교 산학협력단 | Composition for enhancing skin elasticity and improving wrinkles comprising milk exosomes |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007166A1 (en) | 1989-11-16 | 1991-05-30 | Washington State University Research Foundation, Inc | Compositions and methods for reducing the risk of sunlight and ultraviolet induced skin cancer |
WO1992006706A1 (en) | 1990-10-16 | 1992-04-30 | John Lezdey | Treatment of inflammation |
WO1996028008A2 (en) | 1996-03-19 | 1996-09-19 | Guerlain S.A. | Novel cosmetic or dermatological compositions for controlling skin ageing |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US4906457A (en) * | 1988-09-06 | 1990-03-06 | Washington State University Research Foundation, Inc. | Compositions and methods for reducing the risk of sunlight and ultraviolet induced skin cancer |
AU5833994A (en) * | 1993-01-26 | 1994-08-15 | Horse Vitality Ltd. | Pharmaceutical and dermocosmetic compositions containing equine colostrum |
DK85193D0 (en) * | 1993-07-16 | 1993-07-16 | Cancerforskningsfondet Af 1989 | SUPPRESSION OF INHIBITORS |
US5346886A (en) * | 1993-11-15 | 1994-09-13 | John Lezdey | Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin |
ES2169231T3 (en) * | 1995-03-23 | 2002-07-01 | Lancaster Group Gmbh | COSMETIC AGENTS WITH CONDENSED DECOMPOSITION PRODUCTS OF VEGETABLE AND ANIMAL ORIGIN. |
AU720476B2 (en) * | 1996-05-07 | 2000-06-01 | Eric F. Bernstein | Use of tempol in the prevention of photoaging |
GB9621630D0 (en) * | 1996-10-17 | 1996-12-11 | Kappa Pharmaceuticals Ltd | Treatment of skin disorders |
WO2000023038A1 (en) * | 1998-10-21 | 2000-04-27 | Revlon Consumer Products Corporation | Cosmetic compositions containing polysaccharide/protein complexes |
US6096327A (en) * | 1998-11-05 | 2000-08-01 | Protease Sciences Inc. | Cosmetic compositions containing human type serine protease inhibitors for revitalizing the skin |
-
2000
- 2000-02-22 WO PCT/US2000/004427 patent/WO2000050057A1/en active IP Right Grant
- 2000-02-22 JP JP2000600667A patent/JP2002537346A/en active Pending
- 2000-02-22 EP EP00910265A patent/EP1162934A4/en not_active Withdrawn
- 2000-02-22 AU AU32387/00A patent/AU759261B2/en not_active Ceased
- 2000-02-22 CA CA002362565A patent/CA2362565A1/en not_active Abandoned
-
2005
- 2005-02-17 US US11/060,041 patent/US20050208000A1/en not_active Abandoned
-
2012
- 2012-06-22 US US13/531,439 patent/US20120263663A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007166A1 (en) | 1989-11-16 | 1991-05-30 | Washington State University Research Foundation, Inc | Compositions and methods for reducing the risk of sunlight and ultraviolet induced skin cancer |
WO1992006706A1 (en) | 1990-10-16 | 1992-04-30 | John Lezdey | Treatment of inflammation |
WO1996028008A2 (en) | 1996-03-19 | 1996-09-19 | Guerlain S.A. | Novel cosmetic or dermatological compositions for controlling skin ageing |
Non-Patent Citations (5)
Title |
---|
DANG ET AL., NATURE BIOTECHNOLOGY, vol. 15, 1997, pages 146 - 149 |
DATABASE CAPLUS, US NATIONAL OF MEDICINE, (BETHESDA, MD, USA); SEITE ET AL.: "Mexoryl. RTM. SX: a broad absorption UVA filter protects human skin from the effects of repeated suberthemal doses of UVA" * |
HSU-WONG ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 18072 - 18075 |
J. PHOTOCHEM. PHOTOBIOL.,, vol. 44, no. 1, January 1998 (1998-01-01), pages 69 - 76 * |
See also references of EP1162934A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018137400A1 (en) * | 2017-01-26 | 2018-08-02 | 上海交通大学 | Application of cystatins in preparation of drug for treating or preventing ultraviolet light-induced skin damage |
EP3681494A4 (en) * | 2017-09-15 | 2021-08-04 | Ampersand Biopharmaceuticals, Inc. | Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases |
Also Published As
Publication number | Publication date |
---|---|
US20120263663A1 (en) | 2012-10-18 |
EP1162934A1 (en) | 2001-12-19 |
AU3238700A (en) | 2000-09-14 |
JP2002537346A (en) | 2002-11-05 |
EP1162934A4 (en) | 2005-01-26 |
US20050208000A1 (en) | 2005-09-22 |
CA2362565A1 (en) | 2000-08-31 |
AU759261B2 (en) | 2003-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050208000A1 (en) | Compositions and methods for prevention of photoaging | |
Gélis et al. | Assessment of the skin photoprotective capacities of an organo‐mineral broad‐spectrum sunblock on two ex vivo skin models | |
Imokawa et al. | Differential analysis of experimental hypermelanosis induced by UVB, PUVA, and allergic contact dermatitis using a brownish guinea pig model | |
EP3532019B1 (en) | Skin enhancing compositions and methods | |
US20090142285A1 (en) | Cosmetic composition comprising ascorbic acid 2-glucoside and ergothioneine | |
US5302389A (en) | Method for treating UV-induced suppression of contact hypersensitivity by administration of T4 endonuclease | |
KR100978545B1 (en) | Cosmetic use of an extract of Mentha | |
US5840734A (en) | Use of tempol in the prevention of photoaging | |
US6552040B1 (en) | Use of nitroxides in wound healing and in the prevention of photodamage | |
Fourtanier et al. | In vivo evaluation of photoprotection against chronic ultraviolet‐A irradiation by a new sunscreen Mexoryl® SX | |
CN111093622A (en) | Skin care applications of extracellular metabolites from bacillus coagulans | |
US20060029555A1 (en) | Compositions and methods for prevention of photoaging | |
Rouabhia et al. | A physical sunscreen protects engineered human skin against artificial solar ultraviolet radiation-induced tissue and DNA damage | |
Rougier et al. | Protection of the skin against ultraviolet radiations | |
AU720476B2 (en) | Use of tempol in the prevention of photoaging | |
WO2002011738A1 (en) | Cosmetics or dermatological preparations containing polymers having phosphorylcholine side chain | |
KR101081178B1 (en) | Cosmetic composition for inflammation in skin containing Citrullis Vulgaris extract | |
CA2253187C (en) | Use of tempol in the prevention of photoaging | |
TWI664973B (en) | Application of lotus leaf extract for the treatment of pigmentation syndrome | |
KR0155613B1 (en) | Collagenase expression inhibitor containing ursolic acid | |
KR102215164B1 (en) | Composition for preventing or improving skin aging containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester | |
JP2002541774A (en) | System and method for evaluating agents that prevent oxidative damage | |
PL223232B1 (en) | Composition and preparation containing thioproline and ergothioneine, the use of thioproline and ergothioneine and a method for protecting skin against the extrinsic aging process | |
KR20030092204A (en) | Whitening composition for external applications to the skin containing d-fructose 1,6-diphosphate or derivatives thereof | |
JPH04217627A (en) | Tyrosinase activity inhibitor and melanism depressant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2362565 Country of ref document: CA Ref country code: CA Ref document number: 2362565 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 600667 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 32387/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000910265 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000910265 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09913697 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 32387/00 Country of ref document: AU |